Elevated GFAP expression is seen before the onset of clinical symptoms in relapsing–remitting EAE mice, and astrocyte reactivity similarly occurs in the beginning stages of MS lesion formation and persists chronically [31, 32]. This evidence concerns the gene GFAP and myeloid sarcoma.